Synchronoss Technologies (SNCR) Prices 38.4M Offering at $2.6/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
- Qualcomm (QCOM) Reports In-Line Q4 EPS, Beats on Revenue; Offers Q1 Guidance
- Intel shares fall as competitor reports record results
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- SanDisk shares fall on election and chip sector pressure
- Seagate Technology shares drop amid sector selloff
- After-Hours Movers: QCOM, COHR, APP, HUBS, SNAP, FSLY, FIG, ZG, BROS, CDE
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
After-Hours Stock Movers 06/24: (TNXP) (NKE) (SNX) Higher; (TBPH) (SNCR) (FDX) Lower (more...)
June 24, 2021 5:49 PM EDTAfter-Hours Stock Movers
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) 13.6% HIGHER; Dr. Seth Lederman, CEO of Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, said today that plans are advancing to construct a commercial-scale manufacturing facility to develop and manufacture vaccines in the Bitterroot Valley.
Theravance Biopharma, Inc. (NASDAQ: TBPH) 9.2% LOWER; announced today that it intends to offer its ordinary shares in an underwritten public offering. Theravance Biopharma also intends to... More
Synchronoss Technologies (SNCR) to Offer $100M in Common Stock
June 24, 2021 5:32 PM EDTSynchronoss Technologies, Inc. (NASDAQ: SNCR) today announced that the Company intends to offer and sell, subject to market and other conditions, $100 million of shares of its common stock in an underwritten public offering. Synchronoss also expects to grant the underwriters a 30-day option to... More



